LIFESPAN Labs Research Reveals Men’s Beliefs And Behavior Surrounding Erectile Dysfunction

Main Category: Erectile Dysfunction / Premature Ejaculation
Also Included In: Men’s health
Article Date: 16 Sep 2010 – 3:00 PDT

email to a friend   printer friendly   opinions  
<!– rate article

Patient / Public:

2.75 (4 votes)

Healthcare Prof:

Article Opinions: 0 posts

A new poll of men and women over 50 years old reveals that, while most men report some level of erectile dysfunction (ED), women generally aren’t aware of the problem in their partners. The problem extends beyond simple communication since ED can often be a symptom of overall health and well-being in men.

Ban Tobacco Ads And Restrict Alcohol And Erectile Dysfunction Ads, Urges The American Academy Of Pediatrics

Editor’s Choice
Main Category: Pediatrics / Children’s Health
Also Included In: Smoking / Quit Smoking;  Alcohol / Addiction / Illegal Drugs;  Erectile Dysfunction / Premature Ejaculation
Article Date: 27 Sep 2010 – 9:00 PDT

email to a friend   printer friendly   opinions  

Patient / Public:

3.5 (2 votes)

Healthcare Prof:

5 (4 votes)

Article Opinions: 1 posts

The monumental task of persuading children and adolescents to say “No” to drugs, alcohol and tobacco is being constantly undermined by the $25 billions’ worth of advertising and marketing each year, which has precisely the opposite effect, says the American Academy of Pediatrics (AAP). The AAP adds that children should not be exposed to erectile dysfunction ads before ten at night.

Researchers Discover A Drug Combination That Shrinks Prostate Tumors In Vivo

 

Main Category: Prostate / Prostate Cancer
Also Included In: Cardiovascular / Cardiology;  Erectile Dysfunction / Premature Ejaculation
Article Date: 28 Sep 2010 – 3:00 PDT

email to a friend   printer friendly   opinions

Patient / Public:

4.33 (3 votes)

Healthcare Prof:

1 (1 votes)

Article Opinions: 0 posts
Virginia Commonwealth University School of Medicine and VCU Massey Cancer Center researchers have shown that the impotence drug Viagra, in combination with doxorubicin, a powerful anti-cancer drug, enhances its anti-tumor efficacy in prostate cancer while alleviating the damage to the heart at the same time.

Sexual Issues A Major Concern For Cancer Patients Taking New Targeted Drugs

Main Category: Cancer / Oncology
Also Included In: Sexual Health / STDs;  Erectile Dysfunction / Premature Ejaculation
Article Date: 13 Oct 2010 – 0:00 PDT

email to a friend   printer friendly   opinions  

Patient / Public:

5 (1 votes)

Healthcare Prof:

Article Opinions: 0 posts

New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient’s sex life, researchers have found.

NovaDel Pharma Inc. Announces Positive Data From Pilot Pharmacokinetic Study Comparing Duromist™ (Sildenafil Citrate Oral Spray) To Viagra(R)

 

Main Category: Erectile Dysfunction / Premature Ejaculation
Article Date: 20 Oct 2010 – 1:00 PDT

email to a friend   printer friendly   opinions

Patient / Public:

Healthcare Prof:

Article Opinions: 0 posts
NovaDel Pharma Inc. (OTCBB: NVDL), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed pharmaceutical products, announced pharmacokinetic (PK) and safety results from its pilot PK study comparing Duromist™ to Viagra®. Duromist™ is NovaDel’s oral spray formulation of sildenafil citrate. Viagra® is the tablet formulation of sildenafil citrate developed and marketed by Pfizer. Sildenafil citrate is a leading drug indicated for the management of pulmonary hypertension and erectile dysfunction. NovaDel now plans to review the results from this study with the FDA to obtain guidance on defining definitive clinical trial requirements as a pathway to NDA approval.

Apricus Bio Announces First Patent Grant For Femprox(R) In Japan

Main Category: Erectile Dysfunction / Premature Ejaculation
Article Date: 20 Oct 2010 – 2:00 PDT

email to a friend   printer friendly   opinions  

Patient / Public:

Healthcare Prof:

Article Opinions: 0 posts

Apricus Biosciences, Inc., (“Apricus Bio”) (Nasdaq: APRI) backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Japanese Patent Office has issued a Decision to Grant a Patent for the Company’s application on Femprox entitled, “Compositions and Methods for Amelioration of Human Female Sexual Dysfunction.” This patent, when issued, will provide Japanese patent protection to December 2019, and is one in a series of patents and pending applications that Apricus Bio owns on Femprox and the underlying NexACT technology.